Oncolys BioPharma, Inc. (JP:4588)
:4588
Top Page
Oncolys BioPharma, Inc.
(4588)
Select Model
Select Model
Rating:55Neutral
Price Target:
¥2,335.00
▲(145.02% Upside)
Action:ReiteratedDate:03/03/26
The score is held down primarily by weak financial performance—collapsed revenue, persistent large losses, and heavy cash burn—despite a relatively manageable balance sheet. Strong technical momentum lifts the score, while valuation remains constrained by loss-making economics and no dividend support.
Positive Factors
Balance Sheet Strength
Improved leverage and a meaningful rise in equity and assets provide structural liquidity and runway. This reduces near-term refinancing pressure, allows continued clinical R&D funding without immediate solvency stress, and preserves strategic optionality over the coming months.
Negative Factors
Severe Revenue Decline
The dramatic multi-year revenue collapse removes an internal funding base and signals failure to scale commercial or licensing revenue. Structurally low top-line undermines long-term sustainability and forces dependence on external capital or a transformative commercial/clinical success to restore viability.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Improved leverage and a meaningful rise in equity and assets provide structural liquidity and runway. This reduces near-term refinancing pressure, allows continued clinical R&D funding without immediate solvency stress, and preserves strategic optionality over the coming months.
Read all positive factors
Oncolys BioPharma, Inc. (4588) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥68.40B
Dividend YieldN/A
Average Volume (3M)1.52M
Price to Earnings (P/E)―
Beta (1Y)1.98
Revenue Growth-9.04%
EPS Growth13.09%
CountryJP
Employees40
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-15.37
Shares Outstanding29,291,700
10 Day Avg. Volume2,742,450
30 Day Avg. Volume1,517,566
Financial Highlights & Ratios
PEG Ratio-4.72
Price to Book (P/B)8.90
Price to Sales (P/S)1247.26
P/FCF Ratio-18.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Oncolys BioPharma, Inc. Business Overview & Revenue Model
Company Description
Oncolys BioPharma Inc. engages in the research, development, manufacture, sale, import, and export of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the rest of Asia, and the United States. Its product pipeline inclu...
How the Company Makes Money
null...
Oncolys BioPharma, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
21
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 28.55M | 28.55M | 31.38M | 63.04M | 976.18M | 642.49M |
| Gross Profit | 27.68M | 28.30M | 31.38M | 30.61M | 338.49M | 198.80M |
| EBITDA | -2.18B | -2.05B | -1.68B | -1.93B | -1.14B | -1.60B |
| Net Income | -2.24B | -2.06B | -1.68B | -1.94B | -1.15B | -1.62B |
Balance Sheet | ||||||
| Total Assets | 1.93B | 4.56B | 3.20B | 2.04B | 2.65B | 4.29B |
| Cash, Cash Equivalents and Short-Term Investments | 1.39B | 3.72B | 2.41B | 1.53B | 1.71B | 3.45B |
| Total Debt | 366.79M | 320.02M | 324.64M | 315.17M | 393.66M | 503.47M |
| Total Liabilities | 493.35M | 555.91M | 446.65M | 566.50M | 491.69M | 697.88M |
| Stockholders Equity | 1.44B | 4.00B | 2.75B | 1.47B | 2.16B | 3.59B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -1.94B | -2.02B | -1.34B | -1.72B | -1.74B |
| Operating Cash Flow | 0.00 | -1.94B | -2.02B | -1.34B | -1.72B | -1.74B |
| Investing Cash Flow | 0.00 | -7.58M | -4.71M | -5.39M | 20.12M | -942.00K |
| Financing Cash Flow | 0.00 | 3.22B | 2.88B | 1.14B | -113.83M | 3.09B |
Oncolys BioPharma, Inc. Technical Analysis
Neutral
953.00
Price Trends
2303.24
Positive
1712.10
Positive
1183.55
Positive
Market Momentum
-17.02
Positive
47.01
Neutral
39.59
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4588, the sentiment is Neutral. The current price of 953 is below the 20-day moving average (MA) of 2649.70, below the 50-day MA of 2303.24, and below the 200-day MA of 1183.55, indicating a neutral trend. The MACD of -17.02 indicates Positive momentum. The RSI at 47.01 is Neutral, neither overbought nor oversold. The STOCH value of 39.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4588.
Oncolys BioPharma, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | ¥68.40B | -17.30 | ― | ― | -9.04% | 13.09% | |
52 Neutral | ¥138.24B | -8.84 | ― | 2.18% | -0.16% | -802.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥14.73B | -17.96 | ― | ― | ― | 14.03% | |
47 Neutral | ¥7.44B | -7.39 | ― | ― | 25.28% | 39.15% | |
46 Neutral | ¥155.34B | -57.13 | -10.16% | ― | -62.47% | -134.06% | |
46 Neutral | ¥8.44B | -7.89 | -63.25% | ― | 99.87% | 40.60% |
* Healthcare Sector Average
JP:4588
Oncolys BioPharma, Inc.
2,338.00
1,718.00
277.10%
JP:4587
Peptidream
1,196.50
-980.50
-45.04%
JP:4564
OncoTherapy Science
22.00
-6.00
-21.43%
JP:4575
CanBas Co., Ltd.
747.00
-213.00
-22.19%
JP:4583
Chiome Bioscience Inc.
105.00
-40.00
-27.59%
JP:4974
Takara Bio Inc.
1,148.00
320.00
38.65%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.